• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Probiotic Therapy: Level I Evidence for Which Condition?

Article

Probiotic therapy has level 1 evidence for only one condition-acute infectious diarrhea.

Probiotics have been used to manage all of the conditions below. Which of the following is the only condition with Level I evidence (well-conducted, controlled studies)?

A. Acute infectious diarrhea
B. Irritable bowel syndrome
C. Hepatic encephalopathy
D. Clostridium difficile infection

Please click here for the answer and discussion.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
ACG Updates Guidelines for Eosinophilic Esophagitis: Daily Dose / image credit: ©New Africa/AdobeStock

ACG Updates Guidelines for Eosinophilic Esophagitis: Daily Dose

Sydney Jennings
January 16th 2025
Article

Your daily dose of the clinical news you may have missed.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning / Image credit: ©MargJohnsonVA/AdobeStock

FDA Updates RSV Vaccine Labels to Include Guillain-Barré Syndrome Warning

Sydney Jennings
January 8th 2025
Article

The FDA approved the addition of Guillain-Barré syndrome warnings for Abrysvo and Arexvy, citing postmarketing data suggesting an increased risk.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Bird Flu: First US Death Reported, NIH Updates Risk Assessment

Bird Flu: First US Death Reported, NIH Updates Risk Assessment

John Parkinson;Grace Halsey
January 7th 2025
Article

The first death of an American from the H5N1 virus was reported in Louisiana on Monday, though authorities maintain the risk of widespread infection remains low.

Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21 / Image credit: ©Crystal Light/AdobeStock

Sanofi and SK Bioscience Expand Pneumococcal Vaccine Partnership, Launch Phase 3 Trial for PCV21

Sydney Jennings
January 6th 2025
Article

Sanofi and SK bioscience expand collaboration on pneumococcal conjugate vaccines, including a 21-valent candidate for pediatric populations.

© 2025 MJH Life Sciences

All rights reserved.